Shumei Kato Selected Research

Shumei Kato Research Topics

Disease

96	Neoplasms (Cancer) 05/2024 - 01/2012
6	Microsatellite Instability 03/2024 - 01/2019
6	Pancreatic Neoplasms (Pancreatic Cancer) 12/2023 - 05/2014
6	Melanoma (Melanoma, Malignant) 10/2023 - 11/2017
6	Carcinoma (Carcinomatosis) 11/2022 - 01/2012
5	Ovarian Neoplasms (Ovarian Cancer) 11/2023 - 01/2021
5	Breast Neoplasms (Breast Cancer) 11/2022 - 10/2015
4	Adenocarcinoma 01/2022 - 12/2018
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2023 - 11/2017
3	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 01/2019
3	Genomic Instability 11/2021 - 01/2015
2	Lung Neoplasms (Lung Cancer) 01/2024 - 05/2014
2	Exanthema (Rash) 10/2023 - 01/2021
2	Osteosarcoma (Osteogenic Sarcoma) 01/2022 - 12/2015
2	COVID-19 01/2021 - 01/2020
2	Primary Myelofibrosis (Myelosclerosis) 01/2019 - 01/2018
2	Thrombocytopenia (Thrombopenia) 01/2019 - 08/2011
2	Basal Cell Carcinoma (Rodent Ulcer) 01/2018 - 07/2017
2	Venous Thromboembolism 06/2012 - 10/2010
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 02/2024
1	Stevens-Johnson Syndrome (Lyell's Syndrome) 10/2023
1	Dermatitis 10/2023
1	Diarrhea 10/2023
1	Neuroblastoma 10/2023
1	Nausea 10/2023
1	Colonic Neoplasms (Colon Cancer) 01/2023
1	Esophageal Neoplasms (Esophageal Cancer) 01/2023
1	Cholangiocarcinoma 01/2023
1	Circulating Neoplastic Cells 12/2022

Drug/Important Bio-Agent (IBA)

18	Biomarkers (Surrogate Marker)IBA 03/2024 - 10/2015
15	Immune Checkpoint InhibitorsIBA 03/2024 - 08/2017
12	DNA (Deoxyribonucleic Acid)IBA 03/2024 - 12/2015
12	Circulating Tumor DNAIBA 01/2023 - 01/2017
11	RNA (Ribonucleic Acid)IBA 04/2024 - 01/2019
10	Cell-Free Nucleic AcidsIBA 12/2022 - 01/2015
8	Proteins (Proteins, Gene)FDA Link 01/2024 - 10/2010
7	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 05/2024 - 01/2019
5	trametinibIBA 03/2024 - 01/2021
4	LigandsIBA 01/2024 - 01/2018
4	palbociclibIBA 02/2023 - 01/2021
4	ErbB Receptors (EGF Receptor)IBA 01/2022 - 01/2019
4	IntegrinsIBA 12/2017 - 01/2012
3	AntibodiesIBA 05/2024 - 01/2020
3	CrizotinibIBA 02/2023 - 01/2018
3	VemurafenibIBA 02/2023 - 01/2019
3	Everolimus FDA Link 02/2023 - 01/2021
3	NivolumabIBA 01/2023 - 01/2017
2	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 04/2024 - 11/2022
2	larotrectinibIBA 03/2024 - 01/2020
2	pembrolizumabIBA 03/2024 - 11/2022
2	Interleukin-10 (Interleukin 10)IBA 11/2023 - 02/2023
2	B7-H1 AntigenIBA 08/2023 - 01/2023
2	Sorafenib (BAY 43-9006)FDA Link 02/2023 - 01/2021
2	Paclitaxel (Taxol)FDA LinkGeneric 02/2023 - 01/2019
2	Carboplatin (JM8)FDA LinkGeneric 02/2023 - 01/2019
2	human ERBB2 proteinIBA 01/2023 - 01/2016
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 07/2022 - 05/2014
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2022 - 05/2014
2	CyclinsIBA 01/2022 - 01/2021
2	PlatinumIBA 12/2021 - 01/2021
2	COVID-19 VaccinesIBA 05/2021 - 01/2021
2	Interleukin-6 (Interleukin 6)IBA 07/2020 - 01/2020
2	Phosphotransferases (Kinase)IBA 01/2018 - 01/2012
2	Glycoproteins (Glycoprotein)IBA 12/2017 - 01/2012
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2016 - 01/2015
2	Heparin (Liquaemin)FDA LinkGeneric 06/2012 - 08/2011
1	Janus Kinase InhibitorsIBA 05/2024
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 05/2024
1	Agammaglobulinaemia Tyrosine KinaseIBA 05/2024
1	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 04/2024
1	entrectinibIBA 03/2024
1	selpercatinibIBA 03/2024
1	pemigatinibIBA 03/2024
1	dostarlimabIBA 03/2024
1	dabrafenibIBA 03/2024
1	Designer DrugsIBA 03/2024
1	Neuregulin-1 (Neuregulin 1)IBA 02/2024
1	Creatine Kinase (Creatine Phosphokinase)IBA 10/2023
1	naporafenibIBA 10/2023
1	Protein Kinases (Protein Kinase)IBA 10/2023
1	Lipase (Acid Lipase)FDA Link 10/2023
1	Anaplastic Lymphoma KinaseIBA 09/2023
1	Granzymes (Granzyme)IBA 08/2023
1	Serine Proteases (Serine Protease)IBA 08/2023
1	relatlimabIBA 01/2023
1	trastuzumab deruxtecanIBA 01/2023
1	Messenger RNA (mRNA)IBA 01/2023
1	EmulsionsIBA 12/2022
1	hydrogen sulfite (bisulfite)IBA 12/2022
1	epacadostatIBA 11/2022
1	NF-kappa B (NF-kB)IBA 01/2022
1	ixazomibIBA 01/2022
1	Cetuximab (Erbitux)FDA Link 01/2022
1	lenvatinibIBA 01/2022

Therapy/Procedure

48	Therapeutics 03/2024 - 01/2012
21	Immunotherapy 04/2024 - 07/2017
10	Precision Medicine 04/2024 - 01/2015
7	Drug Therapy (Chemotherapy) 02/2023 - 12/2015
2	Aftercare (After-Treatment) 01/2021 - 07/2020
1	Molecular Targeted Therapy 04/2024